基本信息
views: 6
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Professor Radford has had a career long interest in Hodgkin and non-Hodgkin lymphoma. He has undertaken internationally leading research in the field most notably with respect to developing the evidence base for PET scan directed therapy in Hodgkin lymphoma. He took a leading role in the clinical development of brentuximab vedotin. He has a long association with the UK NCRI Lymphoma Clinical Studies Group and was chair from 2011-2017. He currently leads the NIHR Manchester Patient Safety Translational Research Centre’s theme on the oncology tertiary care/primary care interface.
He has a major interest in reducing late treatment toxicity especially in second cancers and in collaboration with Public Health England has led the development of a national database (BARD) of women at high risk of breast cancer following radiotherapy for lymphoma patients under the age of 36. He chairs the Centre for Living Beyond Cancer Science steering committee and is also leading several digital health projects. One of these, RAPID-digital, was recently designated a national exemplar by Health Data Research UK. He has published more than 400 academic papers, been cited in excess of 20,000 times, generated £13m in research funding over the last 5 years and given numerous invited talks most recently in the US and Europe.
He has a major interest in reducing late treatment toxicity especially in second cancers and in collaboration with Public Health England has led the development of a national database (BARD) of women at high risk of breast cancer following radiotherapy for lymphoma patients under the age of 36. He chairs the Centre for Living Beyond Cancer Science steering committee and is also leading several digital health projects. One of these, RAPID-digital, was recently designated a national exemplar by Health Data Research UK. He has published more than 400 academic papers, been cited in excess of 20,000 times, generated £13m in research funding over the last 5 years and given numerous invited talks most recently in the US and Europe.
Research Interests
Papers共 583 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Juan Pablo Alderuccio,Isildinha M. Reis,Mehdi Hamadani, Muthiah Nachiappan, Salman Leslom,Brad S. Kahl,Weiyun Z. Ai,John Radford,Melhem Solh,Kirit M. Ardeshna,Brian T. Hess,Matthew A. Lunning,
crossref(2024)
JOURNAL OF CLINICAL ONCOLOGYno. 1 (2024): 13-+
Juan Pablo Alderuccio,Isildinha M Reis,Mehdi Hamadani, Muthiah Nachiappan, Salman Leslom,Brad S Kahl,Weiyun Z Ai,John Radford,Melhem Solh,Kirit M Ardeshna,Brian T Hess,Matthew A Lunning,
Clinical cancer research : an official journal of the American Association for Cancer Researchno. 1 (2024): 139-149
Haematologicano. 4 (2024): 1184-1193
BLOOD ADVANCESno. 1 (2024): 93-98
Journal of clinical oncology : official journal of the American Society of Clinical Oncologyno. 16 (2024): 1868-1870
HemaSphereno. S3 (2023): e5749555-e5749555
Ann Tivey,Rohan Shotton,Sally Taylor, Rachel Oakley,Sara Summerton,Prerana Huddar, Michael King,Jane Gibson,Charlotte Eastwood,Tim Cooksley,David C. Wong,John Radford
Research Square (Research Square) (2023)
Load More
Author Statistics
#Papers: 598
#Citation: 27995
H-Index: 83
G-Index: 156
Sociability: 8
Diversity: 0
Activity: 5
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn